Title |
Defibrotide in the treatment of hepatic veno-occlusive disease
|
---|---|
Published in |
Hepatic medicine evidence and research, October 2016
|
DOI | 10.2147/hmer.s79243 |
Pubmed ID | |
Authors |
Alessandro Fulgenzi, Maria Elena Ferrero |
Abstract |
Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), represents the most frequent complication in patients in early phase following hematopoietic stem-cell transplantation (HSCT). In its severe form, VOD/SOS can be associated with multiorgan failure and with a mortality rate >80% by day +100. Defibrotide (DF) (a mixture of 90% single-stranded phosphodiester oligonucleotides and 10% double-stranded phosphodiester oligonucleotides derived from controlled depolarization of porcine intestinal mucosal DNA) has been proposed for the treatment of SOS due to its ability to restore thrombo-fibrinolytic balance and protect endothelial cells. The present review highlights why the mechanisms of action of DF allow its successful use in the prevention and treatment of SOS following HSCT. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 4% |
Unknown | 27 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 5 | 18% |
Researcher | 5 | 18% |
Student > Ph. D. Student | 5 | 18% |
Student > Doctoral Student | 2 | 7% |
Student > Bachelor | 1 | 4% |
Other | 3 | 11% |
Unknown | 7 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 36% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 14% |
Agricultural and Biological Sciences | 3 | 11% |
Biochemistry, Genetics and Molecular Biology | 2 | 7% |
Chemistry | 1 | 4% |
Other | 1 | 4% |
Unknown | 7 | 25% |